What is ClinDatrix?
ClinDatrix operates as a global CRO, dedicated to providing world-class performance and quality services at a competitive price point. The company caters to a diverse clientele within the life sciences, encompassing pharmaceutical, biotechnology, and medical device industries. Its operational model emphasizes efficiency and high standards, positioning it as a key partner for organizations navigating complex research and development pathways. The company's commitment to delivering value is a cornerstone of its market strategy, aiming to support innovation across critical healthcare sectors.
How much funding has ClinDatrix raised?
ClinDatrix has raised a total of $898K across 4 funding rounds:
Debt
$150K
Debt
$98K
Debt
$150K
Debt
$500K
Debt (2020): $150K with participation from PPP
Debt (2021): $98K led by PPP
Debt (2024): $150K, investors not publicly disclosed
Debt (2024): $500K featuring Northeast Bank
Key Investors in ClinDatrix
Northeast Bank
Northeast Bank is likely a financial institution providing debt financing solutions, potentially specializing in supporting established businesses and enterprise-level operations through strategic lending.
PPP
Public-Private Partnership
What's next for ClinDatrix?
The recent major strategic investment signals a pivotal phase for ClinDatrix, likely enabling accelerated expansion of its service offerings, technological advancements, and global reach. This capital infusion is expected to bolster its capacity to support a growing pipeline of client projects and potentially explore new market segments or therapeutic areas. The company's strategic focus on maintaining a balance between performance and cost-effectiveness, coupled with this significant backing, positions it for sustained growth and enhanced competitive advantage within the CRO landscape. Future developments may include strategic partnerships or acquisitions to further solidify its market leadership.
See full ClinDatrix company page
